BRCA1 and neoplasm: Details of the genetic mutations, latency, and distribution of metastases of the individual models are summarized in Figure 1A and Table S1A. Cell lines 30200 and 60577, originally developed from GEMMs of serous ovarian cancer (Szabova et al., 2014), which had been engineered to be Trp53−/−, Brca1−/−, and expressed TAg121 (the N-terminal domain of SV40 T antigen), under control of the cytokeratin 18 promoter, to inactivate the tumor suppressor function of Rb. These models are syngeneic in FVB mice and originate from the ovarian surface epithelium.